Infertility
Recent clinical, regulatory, research and industry developments relating to this disease.
Oxidative Stress, Testicular Inflammatory Pathways, and Male Reproduction.
American Society of Clinical Oncology recommendations on fertility preservation in cancer patients.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)
- Q3 2027Comparison of Progesterone-modified Natural Cycle and Hormone Replacement Therapy Cycle for Endometrial Preparation in Single Frozen Blastocyst Transfer
- Q4 2027Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo Transfers
- Q1 2028Eight Weeks of Low Dose hCG Priming in Women With Diminished Ovarian Reserve Undergoing IVF/ICSI - a Randomized Controlled Trial
- Q4 2028A Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of a Human Menopausal Gonadotropin in the Development of Multiple Follicles, Pregnancy, and Cumulative Live Birth as Part of an Assisted Reproductive Technology (ART) Cycle.
Clinical MilestonesView all 11Hide
- 2026-02-12A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme in ChinaResults posted
- 2025-09-19Study the Effects of Intrauterine Flushing With Low Dose Human Chorionic Gonadotropin on Ultrasound Parameter and Immunological Marker of Endometrial Receptivity of Infertile Female Undergoing ICSI CycleResults posted
- 2026-04-29Comparison of Progesterone-modified Natural Cycle and Hormone Replacement Therapy Cycle for Endometrial Preparation in Single Frozen Blastocyst TransferResults expected Q3 2027
- 2026-04-27A Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of a Human Menopausal Gonadotropin in the Development of Multiple Follicles, Pregnancy, and Cumulative Live Birth as Part of an Assisted Reproductive Technology (ART) Cycle.Results expected Q4 2028
- 2026-03-02Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)Results expected Q2 2027
- 2025-12-15Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo TransfersResults expected Q4 2027
- 2025-09-17Eight Weeks of Low Dose hCG Priming in Women With Diminished Ovarian Reserve Undergoing IVF/ICSI - a Randomized Controlled TrialResults expected Q1 2028
- 2026-04-01Oral Estradiol Dose for Endometrial Preparation in Hormone Replacement Frozen Embryo Transfer Cycles: A Randomized Comparative Clinical Trial Comparing 8 mg and 12 mg on Clinical Pregnancy RateCompleted
- 2026-03-11The Impact of the Intensity of Ovarian Stimulation on Embryo Quality in Predicted Suboptimal Responders. A Randomized Controlled TrialCompleted
- 2025-12-31Exploratory Study on the Impact of Different Doses and Route of Administration of Exogenous Progesterone in Artificial Endometrial Preparation Cycles on Endometrial Structure and FunctionCompleted
- 2026-04-29ClinicalComparison of Progesterone-modified Natural Cycle and Hormone Replacement Therapy Cycle for Endometrial Preparation in Single Frozen Blastocyst TransferResults expected Q3 2027
- 2026-04-27ClinicalA Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of a Human Menopausal Gonadotropin in the Development of Multiple Follicles, Pregnancy, and Cumulative Live Birth as Part of an Assisted Reproductive Technology (ART) Cycle.Results expected Q4 2028
- 2026-04-01ClinicalOral Estradiol Dose for Endometrial Preparation in Hormone Replacement Frozen Embryo Transfer Cycles: A Randomized Comparative Clinical Trial Comparing 8 mg and 12 mg on Clinical Pregnancy RateCompleted
- 2026-03-11ClinicalThe Impact of the Intensity of Ovarian Stimulation on Embryo Quality in Predicted Suboptimal Responders. A Randomized Controlled TrialCompleted
- 2026-03-02ClinicalImprovement of Reproductive Function in Men With Spinal Cord Injury (SCI)Results expected Q2 2027
- 2026-02-12ClinicalA Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme in ChinaResults posted
- 2025-12-31ClinicalExploratory Study on the Impact of Different Doses and Route of Administration of Exogenous Progesterone in Artificial Endometrial Preparation Cycles on Endometrial Structure and FunctionCompleted
- 2025-12-15ClinicalBalancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo TransfersResults expected Q4 2027
- 2025-09-19ClinicalStudy the Effects of Intrauterine Flushing With Low Dose Human Chorionic Gonadotropin on Ultrasound Parameter and Immunological Marker of Endometrial Receptivity of Infertile Female Undergoing ICSI CycleResults posted
- 2025-09-17ClinicalEight Weeks of Low Dose hCG Priming in Women With Diminished Ovarian Reserve Undergoing IVF/ICSI - a Randomized Controlled TrialResults expected Q1 2028
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — In the female: Puregon is indicated for the treatment of female infertility in the follow… (1996)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Infertility3
- Aedes1
- Arabidopsis1
- Fertility1
- Medical Oncology1
- Reproductive Medicine1
- Vitamin D Deficiency1
- Wolbachia1
Leading journals6
- Andrology1
- BMC medicine1
- International journal of molecular sciences1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Nature communications1
- Plant biotechnology journal1
Leading researchers8
- Alphey L1
- An X1
- Ant TH1
- Beck LN1
- Blomberg Jensen M1
- Brennan LV1
- Deeks A1
- Dutta S1
Affiliations (unnormalised)6
- Assam University1
- Beijing Engineering Laboratory of Main Crop Bio-Tech Breeding1
- Cardiff University1
- Copenhagen University Hospital - Herlev and Gentofte1
- Copenhagen University Hospital - Rigshospitalet1
- Dana-Farber Cancer Institute1
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Infertility is a reduced or absent capacity to reproduce. In the supplied literature, it is discussed as a reproductive outcome that can arise in both female and male contexts, including in association with cancer treatment and polycystic ovary syndrome.
The grounding supports several causes or contributing conditions, including cancer therapy, polycystic ovary syndrome, inflammation of the male reproductive tract, and oxidative stress. The literature also indicates that infertility can be influenced by genetics, metabolism, lifestyle, bodyweight, ethnicity, and environmental factors in the context of PCOS.
The supplied abstracts link infertility to disrupted reproductive function through different mechanisms. In male infertility, inflammation and oxidative stress are described as core mechanisms that damage reproductive cells and intracellular components, while PCOS is described as a heterogeneous condition with reproductive and metabolic manifestations that affect fertility.
Risk is increased by polycystic ovary syndrome, obesity, insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, and adverse cardiovascular risk profiles. In men, acute or chronic inflammation of the genitourinary tract and oxidative stress are associated with infertility, and cancer treatment is also a context in which fertility is at risk.
The supplied guidance supports fertility preservation methods in people treated for cancer as a management approach related to infertility risk. More broadly, the literature frames treatment at the modality level around fertility preservation and management of underlying reproductive and metabolic conditions, but it does not provide a general standard treatment for infertility itself.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A reduced or absent capacity to reproduce.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.